分子内型预测非特发性肺纤维化间质性肺疾病对免疫抑制治疗的差异反应
Class 2约占30%,其3年无移植生存率显著低于Class 1,且仅在Class 2中观察到免疫抑制治疗(霉酚酸或硫唑嘌呤)的生存获益,分子内型与治疗存在显著交互作用。
要点
- 非IPF ILD可稳定分为2种分子内型,Class 2约占30%且预后更差。
- 免疫抑制治疗的生存获益仅在Class 2中观察到,存在显著交互作用。
- 分子内型有望指导非IPF ILD的精准治疗与临床试验设计。
核心结论
- 在非IPF ILD中识别并验证了2种分子内型,其结局和对免疫抑制治疗的反应存在差异。
- 分子内型可能有助于精准医学策略和ILD临床试验设计。
研究设计与样本
- 多中心观察性队列研究,采用潜在类别分析。
- 发现队列n=676,验证队列n=585,均为非IPF ILD。
- 主要结局为3年无移植生存;采用加权Cox回归评估分子内型与免疫抑制治疗的交互作用。
主要发现
- 2类模型在发现和验证队列中均拟合最佳(P <0.01),Class 2约占30%。
- Class 2较Class 1的3年无移植生存率显著更低:发现队列78% vs 36%(P <0.001),验证队列83% vs 46%(P <0.001)。
- 分子内型与免疫抑制暴露存在显著交互作用:发现队列Pinteraction = 0.022,验证队列Pinteraction = 0.019。
- 生存获益仅在Class 2中观察到;汇总分析中不同ILD亚型趋势相似。
- 通路分析支持Class 2富集炎症信号。
关键数值与推荐
- 2类模型为最佳拟合(P <0.01),Class 2约占30%。
- Class 2的3年无移植生存率:发现队列36% vs Class 1的78%(P <0.001);验证队列46% vs 83%(P <0.001)。
- 分子内型与免疫抑制治疗的交互作用P值:发现队列0.022,验证队列0.019。
临床怎么用
- 对非IPF ILD患者可考虑基于血浆炎症蛋白的分子内型分类以评估预后。
- 免疫抑制治疗(霉酚酸或硫唑嘌呤)的决策可参考分子内型,Class 2可能更可能获益。
- 该分类有助于在临床试验中富集可能获益的人群。
局限性
- 研究为观察性队列,不能确立因果关系。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Interstitial lung diseases (ILDs) are a clinically and biologically diverse group of disorders characterized by varying inflammation and fibrosis of the lung parenchyma. Immunosuppressant therapy is commonly used to treat non-idiopathic pulmonary fibrosis (non-IPF) ILD, but treatment response is variable and difficult to predict. OBJECTIVE: Identify and validate molecular endotypes of non-IPF ILD. METHODS: Twenty plasma proteins associated with inflammation were used to perform latent class analysis in 2 observational non-IPF ILD cohorts (discovery n = 676; validation n = 585). Proteins were measured using a semi-quantitative Olink Explore 3072 platform. The primary outcome was 3-year transplant-free survival. Weighted Cox regression was used to assess differential response to mycophenolate or azathioprine in each cohort according to molecular endotype classification. RESULTS: A 2-class model best fit both cohorts (P <0.01), with Class 2 comprising ∼30% of patients. Compared to Class 1, Class 2 was associated with significantly lower 3-year transplant-free survival in both discovery (78% vs 36%, P <0.001) and validation (83% vs 46%, P <0.001) cohorts. Significant interaction between molecular endotype and immunosuppressant exposure was observed in both cohorts (discovery Pinteraction = 0.022; validation Pinteraction = 0.019), with survival benefit seen only in Class 2. In pooled analysis, similar trends were observed irrespective of ILD subtype. Pathway analysis supported enrichment of inflammatory signatures in Class 2. CONCLUSION: In this multicenter observational cohort study, we identified and validated 2 distinct molecular endotypes of non-IPF ILD with divergent outcomes and response to immunosuppressant therapy. These endotypes could inform precision medicine strategies and clinical trial design in ILD.
引用
- Maddali MV, Pugashetti JV, Pienkos SM, et al. Molecular endotypes predict differential response to immunosuppressant therapy in non-idiopathic pulmonary fibrosis interstitial lung disease. Am J Respir Crit Care Med. 2026. PMID: 41738192. doi:10.1093/ajrccm/aamag006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。